Multicenter Registry of Patients With Subarachnoid Hemorrhage
MEASURE
1 other identifier
observational
1,000
1 country
9
Brief Summary
The purpose of this registry is to collect detailed information on the characteristics, treatment, and outcomes of patients with a subarachnoid hemorrhage. This information will enable research aimed at improving the safety and effectiveness of current and future treatments. By studying these data, the investigators aim to identify which treatment strategies offer the best results and which factors are most important in the care of patients with a subarachnoid hemorrhage. The knowledge gained from this research will help improve patient care in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2024
Longer than P75 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 12, 2024
CompletedFirst Submitted
Initial submission to the registry
March 9, 2026
CompletedFirst Posted
Study publicly available on registry
March 19, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
March 19, 2026
March 1, 2026
2.5 years
March 9, 2026
March 15, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.
6 months ± 30 days after SAH
Secondary Outcomes (14)
modified Rankin Scale (mRS)
18 months ± 30 days after SAH
Complications related to treatment of the ruptured aneurysm
Periprocedural
Complications related to SAH
During registry period (up to 18 months after SAH)
Degree of aneurysm occlusion
Up to 18 months after SAH
Newly found aneurysm or other vascular malformation at additional imaging in patients with non-perimesencephalic primary angiogram negative SAH
Up to 18 months after SAH
- +9 more secondary outcomes
Study Arms (1)
Spontaneous Subarachnoid Hemorrhage
Interventions
Eligibility Criteria
Patients with spontaneous subarachnoid hemorrhage
You may qualify if:
- Age ≥ 18 years
- Spontaneous subarachnoid hemorrhage with blood in the basal cisterns and/or major fissures on non-contrast head computed tomography (CT), or xanthochromia of cerebrospinal fluid confirmed by spectrophotometric analysis.
- Eligible etiologies/patterns:
- Aneurysmal SAH
- SAH from other intracranial vascular malformation (e.g. AVM, dural AVF)
- Perimesencephalic SAH
- Non-perimesencephalic angiogram negative SAH
- SAH from intracranial artery dissection
You may not qualify if:
- Traumatic, neoplastic, infection related (except mycotic aneurysms), or iatrogenic SAH
- Isolated convexity SAH
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UMC Utrechtlead
- Dutch Heart Foundationcollaborator
- The Dutch Brain Foundationcollaborator
- Radboud University Medical Centercollaborator
- Erasmus Medical Centercollaborator
- Maastricht University Medical Centercollaborator
- Elisabeth-TweeSteden Ziekenhuiscollaborator
- Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)collaborator
- Isalacollaborator
- Medical Center Haaglandencollaborator
- University Medical Center Groningencollaborator
Study Sites (9)
Radboud University Medical Center
Nijmegen, Gelderland, 6525 GA, Netherlands
Maastricht University Medical Center+
Maastricht, Limburg, 6229 HX, Netherlands
Elisabeth-Tweesteden Hospital
Tilburg, North Brabant, 5022GC, Netherlands
Amsterdam University Medical Center
Amsterdam, North Holland, 1105AZ, Netherlands
Isala
Zwolle, Overijssel, 8025 AB, Netherlands
University Medical Center Groningen
Groningen, Provincie Groningen, 9713 GZ, Netherlands
Erasmus University Medical Center
Rotterdam, South Holland, 3015 GD, Netherlands
Haaglanden Medical Center
The Hague, South Holland, 2512 VA, Netherlands
Utrecht University Medical Center
Utrecht, Utrecht, 3584 CX, Netherlands
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 18 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
March 9, 2026
First Posted
March 19, 2026
Study Start
February 12, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
February 1, 2028
Last Updated
March 19, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
Upon reasonable request: For each study using the data of this registry, analyses will be performed according to a predefined analysis plan with clearly defined statistical methods. These plans will be prepared prior to data analysis and in accordance with relevant reporting standards, such as the STROBE guideline. All data requests and accompanying statistical analysis plans will be reviewed by an independent research committee affiliated with CONTRAST-2 (the Data Access and Writing Committee) to ensure appropriate use of the registry data.